Covance acquires Medaxial
CRO Covance has acquired Medaxial, a London-based value communication consultancy. The company specializes in an integrated approach to market access strategy, health economic modeling and data dissemination services, and focuses on defining and communicating the value of a biopharmaceutical product or medical device to healthcare payers and the stakeholders who influence them.
“Medaxial, with their proven expertise in optimizing data-driven, solution-focused communication of a medical product’s value, will further complement our market access offerings,” said Marc Ginsky, vice president and general manager, Covance market access. “Proactive and effective communication of clinical and economic value is critical to help clients navigate an increasingly complex drug development and payment landscape, as they strive to provide innovative medical products to patients.”
Covance’s market access services, which currently has offices in Maryland, Indiana, California and Australia, will be better positioned to serve clients worldwide with the addition of Medaxial’s corporate headquarters in London and employees in New York and Belgium.
Paul Mcloughlin, co-founder and director of technology and design at Medaxial, and John Fanshawe, co-founder and managing director, will continue with the company after the acquisition is completed.